Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREPAMIR-SOC: Standard of Care Arm for Gene Therapy Trial in Severe Sickle Cell Disease
NCT07752043Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of DREAM01 in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
DREAM01
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07752043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752043.